2016 American Transplant Congress
Long-Term Outcomes in Epstein-Barr Virus (EBV)-Positive Patients Receiving Belatacept (Bela) or Cyclosporine (CsA) in BENEFIT-EXT.
At 7 yrs post transplant in BENEFIT-EXT (NCT00114777), bela-treated pts had similar graft survival and improved renal function vs CsA-treated pts. Bela is indicated for…2016 American Transplant Congress
Outcomes in Black vs Non-Black Patients Administered Belatacept (Bela) or Cyclosporine (CsA) in BENEFIT.
Studies consistently show worse outcomes for black vs non-black kidney transplant recipients. At 7 yrs post-transplant in BENEFIT, bela was associated with superior graft survival…2016 American Transplant Congress
A Change in Insulin Sensitivity and Lipid Profile in Renal Transplant Recipients Converted from Cyclosporine or Standard Release Tacrolimus to Once-Daily Prolonged Release Tacrolimus.
Background : New-onset diabetes after transplantation may be associated with the use of tacrolimus (Tac) causing impaired insulin release or reduced insulin sensitivity. And, dyslipidemia…2016 American Transplant Congress
Preservation of Alloreactive and Antiviral Immunity After Switch to Belatacept-Based Regimen After Kidney Transplantation.
Purpose: We set out to investigate the impact of switch from calcineurin inhibitor (CNI) to belatacept on T cell mediated allo- and EBV-specific immunity.Methods: We…2016 American Transplant Congress
Conversion to Belatacept as Rescue Therapy in Kidney Transplant Recipients with Severe Graft Dysfunction.
Belatacept is a fusion protein that prevents T cell co-stimulation via the CD28 receptor. If used as first-line therapy, immunosuppression with Belatacept is associated with…2016 American Transplant Congress
Two-Year Safety Results from the Phase 3b Switching Study of Kidney Transplant Patients with Tremor to LCP-Tacro (STRATO) Study.
Tremor is a common side effect of tacrolimus (tac) correlated with peak-dose drug concentration. Envarsus XR®, a novel, once-daily, extended-release formulation of tac, has a…2016 American Transplant Congress
Incidence of Infectious Disease and Malignancies After Rituximab Therapy in Kidney-Transplant Recipients.
1Nephrology, Charité, Berin, Germany; 2Rheumatology, Charité, Berlin, Germany.
BACKGROUND:Rituximab off-label use is common in solid organ transplantation. It is used in patients with antibody-mediated rejections, in AB0-incompatible renal transplantation, in pre-sensitized organ recipients…2016 American Transplant Congress
Schisandra Sphenanthera Extract Facilitates Anti-Tuberculosis Treatment Post Renal Transplantation Through Increasing Bioavailability of Tacrolimus.
Background: Hepatoprotective agent Schisandra sphenanthera extract (SchE) facilitates rifampicin-containing anti-tuberculosis (TB) chemotherapy by stabilizing the Tacrolimus (FK506) blood concentration through increasing the oral bioavailability, which…2016 American Transplant Congress
Belatacept Conversion in Adult Kidney Transplant Recipients for Cause: A Single Center Observational Cohort.
Background: Calcineurin inhibition (CNI) is the single most effective strategy to prevent allograft rejection however tolerability is limited by toxicity. To date, alternate strategies have…2016 American Transplant Congress
Impact of Everolimus and Low-Dose Ciclosporin on Cytomegalovirus Replication and Disease in Pediatric Renal Transplantation.
Purpose: Preclinical studies indicate an anti-cytomegalovirus (CMV) activity of the mammalian target of rapamycin inhibitor (mTORi) everolimus (EVR), but data in pediatric renal transplant recipients…
American Transplant Congress abstracts